A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma

Feng Jin,1,2 Hui Zhu,1,2 Fang Shi,1,2 Li Kong,1,2 Jinming Yu1,21Department of Radiation Oncology, Shandong Cancer Hospital and Institute, 2Shandong Academy of Medical Sciences, University of Jinan, Jinan, Shandong Province, People’s Republic of ChinaPurpose: The aim of this retrospective s...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jin F, Zhu H, Shi F, Kong L, Yu J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	nab-paclitaxel squamous non-small cell lung cancer second-line elderly Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/af533ff75ea44d7e8f41bb41d50639de
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:af533ff75ea44d7e8f41bb41d50639de
record_format	dspace
spelling	oai:doaj.org-article:af533ff75ea44d7e8f41bb41d50639de2021-12-02T06:11:38ZA retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma1178-1998https://doaj.org/article/af533ff75ea44d7e8f41bb41d50639de2016-02-01T00:00:00Zhttps://www.dovepress.com/a-retrospective-analysis-of-safety-and-efficacy-of-weekly-nab-paclitax-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Feng Jin,1,2 Hui Zhu,1,2 Fang Shi,1,2 Li Kong,1,2 Jinming Yu1,21Department of Radiation Oncology, Shandong Cancer Hospital and Institute, 2Shandong Academy of Medical Sciences, University of Jinan, Jinan, Shandong Province, People’s Republic of ChinaPurpose: The aim of this retrospective study was to investigate the anticancer effect and toxicity of weekly administered nab-paclitaxel as a second-line chemotherapy in elderly patients with relapsed squamous non-small-cell lung cancer (NSCLC).Patients and methods: We retrospectively reviewed the treatment of 42 elderly patients with relapsed squamous NSCLC, who received nab-paclitaxel monotherapy as a second-line treatment from January 2010 to March 2014. A dose of 100 mg/m2 nab-paclitaxel was administered weekly on days 1, 8, and 15, followed by 1 week of rest. The protocol was maintained for at least two cycles.Results: The overall response rate (ORR) and the disease control rate (DCR) were 21.43% (9/42) and 47.62% (20/42), respectively. The median progression-free survival (PFS) and overall survival (OS) were 6.6 and 10.9 months, respectively. In the subgroup analysis, there was no significant difference in ORR, DCR, PFS, and OS, accounting for the first-line therapy factors (taxane agent, radiotherapy, or surgery). There was a statistically significant difference in DCR for stages III and IV (62.96% vs 20%, P=0.008), but there was no such difference in either PFS or OS. The ORR of 29 patients receiving more than three cycles of treatment was higher than that of those receiving less than three cycles of treatment (31.03% vs 0%, P=0.038), and there was a significant difference in PFS (7.6 vs 4.9 months, P=0.004) and OS (11.7 vs 8.9 months, P=0.002). No hypersensitivity reactions or treatment-related grade 4 adverse events were reported.Conclusion: Nab-paclitaxel monotherapy administered weekly at a dose of 100 mg/m2 is shown to be an effective and safe regimen for elderly patients with relapsed squamous NSCLC, especially for patients with stage III disease or good performance status.Keywords: nab-paclitaxel, squamous, non-small-cell lung cancer, second line, elderlyJin FZhu HShi FKong LYu JDove Medical Pressarticlenab-paclitaxelsquamousnon-small cell lung cancersecond-lineelderlyGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 11, Pp 167-173 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	nab-paclitaxel squamous non-small cell lung cancer second-line elderly Geriatrics RC952-954.6
spellingShingle	nab-paclitaxel squamous non-small cell lung cancer second-line elderly Geriatrics RC952-954.6 Jin F Zhu H Shi F Kong L Yu J A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma
description	Feng Jin,1,2 Hui Zhu,1,2 Fang Shi,1,2 Li Kong,1,2 Jinming Yu1,21Department of Radiation Oncology, Shandong Cancer Hospital and Institute, 2Shandong Academy of Medical Sciences, University of Jinan, Jinan, Shandong Province, People’s Republic of ChinaPurpose: The aim of this retrospective study was to investigate the anticancer effect and toxicity of weekly administered nab-paclitaxel as a second-line chemotherapy in elderly patients with relapsed squamous non-small-cell lung cancer (NSCLC).Patients and methods: We retrospectively reviewed the treatment of 42 elderly patients with relapsed squamous NSCLC, who received nab-paclitaxel monotherapy as a second-line treatment from January 2010 to March 2014. A dose of 100 mg/m2 nab-paclitaxel was administered weekly on days 1, 8, and 15, followed by 1 week of rest. The protocol was maintained for at least two cycles.Results: The overall response rate (ORR) and the disease control rate (DCR) were 21.43% (9/42) and 47.62% (20/42), respectively. The median progression-free survival (PFS) and overall survival (OS) were 6.6 and 10.9 months, respectively. In the subgroup analysis, there was no significant difference in ORR, DCR, PFS, and OS, accounting for the first-line therapy factors (taxane agent, radiotherapy, or surgery). There was a statistically significant difference in DCR for stages III and IV (62.96% vs 20%, P=0.008), but there was no such difference in either PFS or OS. The ORR of 29 patients receiving more than three cycles of treatment was higher than that of those receiving less than three cycles of treatment (31.03% vs 0%, P=0.038), and there was a significant difference in PFS (7.6 vs 4.9 months, P=0.004) and OS (11.7 vs 8.9 months, P=0.002). No hypersensitivity reactions or treatment-related grade 4 adverse events were reported.Conclusion: Nab-paclitaxel monotherapy administered weekly at a dose of 100 mg/m2 is shown to be an effective and safe regimen for elderly patients with relapsed squamous NSCLC, especially for patients with stage III disease or good performance status.Keywords: nab-paclitaxel, squamous, non-small-cell lung cancer, second line, elderly
format	article
author	Jin F Zhu H Shi F Kong L Yu J
author_facet	Jin F Zhu H Shi F Kong L Yu J
author_sort	Jin F
title	A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma
title_short	A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma
title_full	A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma
title_fullStr	A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma
title_full_unstemmed	A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma
title_sort	retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/af533ff75ea44d7e8f41bb41d50639de
work_keys_str_mv	AT jinf aretrospectiveanalysisofsafetyandefficacyofweeklynabpaclitaxelassecondlinechemotherapyinelderlypatientswithadvancedsquamousnonsmallcelllungcarcinoma AT zhuh aretrospectiveanalysisofsafetyandefficacyofweeklynabpaclitaxelassecondlinechemotherapyinelderlypatientswithadvancedsquamousnonsmallcelllungcarcinoma AT shif aretrospectiveanalysisofsafetyandefficacyofweeklynabpaclitaxelassecondlinechemotherapyinelderlypatientswithadvancedsquamousnonsmallcelllungcarcinoma AT kongl aretrospectiveanalysisofsafetyandefficacyofweeklynabpaclitaxelassecondlinechemotherapyinelderlypatientswithadvancedsquamousnonsmallcelllungcarcinoma AT yuj aretrospectiveanalysisofsafetyandefficacyofweeklynabpaclitaxelassecondlinechemotherapyinelderlypatientswithadvancedsquamousnonsmallcelllungcarcinoma AT jinf retrospectiveanalysisofsafetyandefficacyofweeklynabpaclitaxelassecondlinechemotherapyinelderlypatientswithadvancedsquamousnonsmallcelllungcarcinoma AT zhuh retrospectiveanalysisofsafetyandefficacyofweeklynabpaclitaxelassecondlinechemotherapyinelderlypatientswithadvancedsquamousnonsmallcelllungcarcinoma AT shif retrospectiveanalysisofsafetyandefficacyofweeklynabpaclitaxelassecondlinechemotherapyinelderlypatientswithadvancedsquamousnonsmallcelllungcarcinoma AT kongl retrospectiveanalysisofsafetyandefficacyofweeklynabpaclitaxelassecondlinechemotherapyinelderlypatientswithadvancedsquamousnonsmallcelllungcarcinoma AT yuj retrospectiveanalysisofsafetyandefficacyofweeklynabpaclitaxelassecondlinechemotherapyinelderlypatientswithadvancedsquamousnonsmallcelllungcarcinoma
_version_	1718400069396332544

A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma

Ejemplares similares